News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

Episodes in this series

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

3 experts are featured in this series.

EP. 2 Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

3 experts are featured in this series.

EP. 3 How Bispecific Antibodies Are Reshaping Cancer Care

3 experts are featured in this series.

EP. 4 Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

3 experts are featured in this series.

EP. 5 Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

3 experts are featured in this series.

EP. 6 Overcoming Key Operational Challenges in Integrating Bispecific Therapies

3 experts are featured in this series.

EP. 7 Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

3 experts are featured in this series.

EP. 8 Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

3 experts are featured in this series.

EP. 9 Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

3 experts are featured in this series.

EP. 10 Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

3 experts are featured in this series.

EP. 11 Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

3 experts are featured in this series.

EP. 12 Payer and Reimbursement Considerations for Bispecific Therapies

3 experts are featured in this series.

EP. 13 Emerging Therapeutic Areas for Bispecific Antibodies

3 experts are featured in this series.

EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

3 experts are featured in this series.

EP. 15 Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What are the benefits of implementing/operationalizing bispecifics in the community oncology setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Peptide vial | Image credit: Iurii - stock.adobe.com

FDA Panel Backs 6 Peptides for Compounding

ByPearl Steinzor

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer